Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar.

Hiam ChemaitellyPatrick TangMohammad R HasanSawsan AlMukdadHadi M YassineFatiha M BenslimaneHebah A Al KhatibPeter CoyleHoussein H AyoubZaina Al KanaaniEinas Al KuwariAndrew JeremijenkoAnvar H KaleeckalAli N LatifRiyazuddin M ShaikHanan F Abdul RahimGheyath K NasrallahMohamed G Al KuwariHamad E Al RomaihiAdeel Ajwad ButtMohamed H Al-ThaniAbdullatif Al KhalRoberto BertolliniLaith Jamal Abu-Raddad

Published in: The New England journal of medicine (2021)

BNT162b2-induced protection against SARS-CoV-2 infection appeared to wane rapidly following its peak after the second dose, but protection against hospitalization and death persisted at a robust level for 6 months after the second dose. (Funded by Weill Cornell Medicine-Qatar and others.).

Keyphrases

respiratory syndrome coronavirus
high glucose
diabetic rats
oxidative stress
sars cov
coronavirus disease